Antiviral Drugs on the Treatment of SARS-CoV-2

Astana Medical University150 enrolled

Overview

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Complication of Medical Care Pneumonia, Viral

Interventions

FavipiravirDRUG

Antiviral drugs

RemdesivirDRUG

Antiviral drugs

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: main group * Patients with COVID19 with medium and easy condition disease * take favipiravir/remdisivir control group * Patients with COVID19 with medium and easy condition disease * not take favipiravir/remdisivir Exclusion Criteria: * patients younger 18 * severe conditionis

Locations (2)

Aidos Konkaev

Astana, Kazakhstan

Semey Medical University

Semey, Kazakhstan

Outcomes

Primary Outcomes

Outcome without comlications

The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2

Time frame: 14 days

Secondary Outcomes

Heart rate

Measure

Time frame: 14 days

SpO2

Measure

Time frame: 14 days

Blood pressure

Measure

Time frame: 14 days

Respiratory rate

Measure

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.